Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Seeking Alpha / 21 hours ago 2 Views
Comments